Richard Saynor, Sandoz CEO
June 15, 2023 02:41 PM EDT
Pharma
FDA+

San­doz un­veils glob­al ac­tion plan to im­prove ac­cess to biosim­i­lars

Nicole DeFeudis

Editor

As the spot­light trains on ac­cess to biosim­i­lars, No­var­tis’ gener­ics unit on Thurs­day re­leased a glob­al ac­tion plan to boost biosim­i­lar adop­tion by 2030. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force in lat­est job cuts

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

A service from the Financial Times